Advocacy intelligence hub — real-time data for patient organizations
HepaGam B: FDA approved
Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
HepaGam B
Cangene Corporation
Patient Assistance Programs1
MAVYRET
AbbVie, Inc.
HepaGam B
(hepatitis B immune globulin (human))Orphan drugCangene Corporation
Human Immunoglobulin [EPC]
Aminocaproic Acid
(AMINOCAPROIC ACID)Orphan drugstandardAmerican Regent, Inc.
Antifibrinolytic Agent [EPC]
MAVYRET
(glecaprevir and pibrentasvir)Orphan drugstandardAbbVie, Inc.
Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]
12.1 Mechanism of Action Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral ag...
Browse all Hepatitis B reinfection following liver transplantation news →
Michael P Manns, MD, DC
Hannover Medical School
📍 GRESHAM, OR
Heiner Wedemeyer, MD
Hannover Medical School
View all Hepatitis B reinfection following liver transplantation specialists →